Acetylglutamic Acid

Acetylglutamic Acid

SCHEMBL716411

CC(=O)N[C@H](CCC(=O)O)C(=O)O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 8/20 0.69
▸ NAALAD2 Q9Y3Q0 3/20 0.69
▸ RIMKLA Q8IXN7 1/20 0.69
▸ KDM4E B2RXH2 1/20 0.57
▸ MAPT P10636 1/20 0.57
▸ THRB P10828 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ NFKB1 P19838 1/20 0.57
▸ PTGS2 P35354 1/20 0.57
▸ THPO P40225 1/20 0.57
▸ RECQL P46063 1/20 0.57
▸ BLM P54132 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.55
▸ GNPAT O15228 1/20 0.54
▸ GGH Q92820 1/20 0.53
▸ FNTA P49354 2/20 0.50
▸ FNTB P49356 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetylglutamic Acid SCHEMBL82128 1.00 FOLH1 (0.69) FOLH1NAALAD2RIMKLAKDM4EMAPT
Acetylglutamic Acid SCHEMBL2512801 1.00 FOLH1 (0.69) FOLH1NAALAD2RIMKLAKDM4EMAPT
Aceglumate SCHEMBL198970 1.00 FOLH1 (0.69) FOLH1NAALAD2RIMKLAKDM4EMAPT
Acetylglutamic Acid SCHEMBL31621391 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAKDM4EMAPT
Acetylglutamic Acid SCHEMBL11403044 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAKDM4EMAPT
Acetylglutamic Acid SCHEMBL31621403 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAKDM4EMAPT
Acetylglutamic Acid SCHEMBL11793383 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAKDM4EMAPT
Acetylglutamic Acid SCHEMBL31621384 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAKDM4EMAPT
Aceglumate SCHEMBL11403040 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAKDM4EMAPT
Acetylglutamic Acid SCHEMBL11403051 0.98 FOLH1 (0.67) FOLH1NAALAD2RIMKLAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117789993-A Establishment and application of gastric cancer prediction model based on tongue fur metabolite 浙江省肿瘤医院 2024-03-29 — — CN claimed
CN-115876826-A Method for judging absolute configuration of oseltamivir 北京格林意锐医药科技有限责任公司 2023-03-31 — — CN claimed
CN-107778234-B Preparation method of neuromuscular blocker intermediate 四川科瑞德制药股份有限公司 2023-01-06 — — CN claimed
CN-115090225-A Novel efficient aldehyde-removing transparent gel and preparation method thereof 重庆中科力泰高分子材料股份有限公司 2022-09-23 — — CN claimed
CN-114716375-A Preparation method of tetrahydrobenzyl isoquinoline compound 四川科瑞德制药股份有限公司 2022-07-08 — — CN claimed
CN-113984814-A Method for determining structure and absolute configuration of chiral sample by using MicroED technology 无锡佰翱得生物科学有限公司 2022-01-28 — — CN claimed
EP-2183201-B1 PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS ESTEVE QUIMICA SA (ES) 2012-03-28 — — EP claimed
US-7968712-B2 Process for the resolution of zopiclone and intermediate compounds ESTEVE QUIMICA, S.A. (ES) 2011-06-28 — — US claimed
US-20100274018-A1 PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS ESTEVE QUIMICA, S.A. (ES) 2010-10-28 — — US claimed
US-7772396-B2 Process for the resolution of zopiclone and intermediate compounds Esteve Quimica, S.A. Avda. Mare de deu de Monsterrat (ES) 2010-08-10 — — US claimed
CN-101772475-A Method and intermediate compounds for resolving zopiclone ESTEVE QUIMICA SA 2010-07-07 — — CN claimed
EP-2183201-A1 PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS Esteve Química, S.A. (ES) 2010-05-12 — — EP claimed
WO-2009016251-A1 PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS Esteve Química, S.A. (ES) 2009-02-05 — — WO claimed
US-20090036681-A1 PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS ESTEVE QUIMICA, S.A. (ES) 2009-02-05 — — US claimed
EP-2020403-A1 Process for the resolution of zopiclone and intermediate compounds ESTEVE QUIMICA, S.A. (ES) 2009-02-04 — — EP claimed
CN-1874992-A Resolution of 3-amino alkylnitriles PFIZER (US) 2006-12-06 — — CN claimed
EP-1689703-A1 RESOLUTION OF 3-AMINO ALKYLNITRILES Pfizer Products Inc. (US) 2006-08-16 — — EP claimed
US-7026345-B2 Resolution of 3-amino alkylnitriles PFIZER INC. (US) 2006-04-11 — — US claimed
US-20050107453-A1 Resolution of 3-amino alkylnitriles PFIZER INC. 2005-05-19 — — US claimed
WO-2005040097-A1 RESOLUTION OF 3-AMINO ALKYLNITRILES PFIZER PRODUCTS INC. (US) 2005-05-06 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100274018-A1 PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS CYP3A5, ZP1, AZI2 FOLH1 1911/4885NAALAD2 629/4885RIMKLA 528/4885
US-20050107453-A1 Resolution of 3-amino alkylnitriles AADAT, AANAT, AAAS FOLH1 3707/4885NAALAD2 13/4885RIMKLA 11/4885
US-20090036681-A1 PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS CYP3A5, ZP1, AZI2 FOLH1 1911/4885NAALAD2 629/4885RIMKLA 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback